Abbott has reported data from five late-breaking presentations demonstrating the advantages of its minimally invasive devices that are designed to treat people with various structural heart diseases.
The new data of the company’s minimally invasive structural heart technologies were presented at the 34th Transcatheter Cardiovascular Therapeutics (TCT) annual scientific meeting of the Cardiovascular Research Foundation in Boston.
It includes results that strengthen the effectiveness and safety of the transcatheter edge-to-edge repair (TEER) device, MitraClip, in treating the leaking valves in mitral regurgitation (MR) patients.
